Links
FDA reverses its decision and will now review the Moderna flu vaccine. Could Australia be a model for FDA reform? “Pharma signals it’s done negotiating” Giant viruses. Hairy ball theorem.
Unbiased Analysis of Today's Healthcare Issues
FDA reverses its decision and will now review the Moderna flu vaccine. Could Australia be a model for FDA reform? “Pharma signals it’s done negotiating” Giant viruses. Hairy ball theorem.
Expert opinions: Will MFN reduce US drug prices? Robots in maternity care. What drives company decisions on new medicine launches and UK investment? Incorporating dynamic pricing into HEOR models (dynamicpv) Tale of 2 value sets. How to handle the lows? Honesty. Integrity in journalism: Giannis edition.
Regulation and Theory of the Adjacent Possible. Alex Taborrok on Trump pharmaceutical plan. Double negotiation? IRA + MFN. Mass General Brigham will provide AI pre-visits. Are ‘mobile crisis’ teams in crisis?
From CMS yesterday: On January 27, 2026, CMS announced the selection of the below list of 15 drugs payable under Medicare Part B and/or covered under Medicare Part D for the third cycle of negotiations (initial price applicability year 2028), based on total expenditures for drugs payable under Part B and/or covered under Part D…
President Trump unveiled “The Great Healthcare Plan” on January 15, 2026, calling on Congress to reduce prescription drug prices, lower insurance premiums, and increase healthcare price transparency. The plan proposes four main components: codifying Most-Favored-Nation (MFN) drug pricing agreements that the administration has negotiated with 16 pharmaceutical manufacturers, targeting prices at the lowest international levels;…
Life science options for commercialization success. There were fewer births in China in 2025 than in 1776. The end of vaccine development? “Medicare Part D led to a slower increase in AMR-related inpatient discharges” Is mobility the missing quality measure?
ChatGPT introduces OpenAI for Healthcare. AI can make prescription renewals in Utah. AMA’s perspective of physicians role with AI. US Army’s use of AI to improve soldiers’ mental health. Claim the AI skill boost.
FDA Qualifies First AI Drug Development Tool in MASH. No impact of Medicaid on crime rates. “The life of an artist is…” Elasticity of disability insurance (DI) takeup to DI generosity: 1.26 Do it anyway.
The licensing racket. Meta is not a monopoly. KFF debate on drug pricing in the US. Use of AI by pharmaceutical manufacturers. FDA and agentic AI.
That is the news out of the UK today. A press release from the United Kingdom government states: A 25% increase in medicine pricing corresponds to 2 changes to the way NICE evaluates medicines; a change to the cost effectiveness thresholds and the introduction of a new value set for judging health states.NICE currently assesses value for money…